Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-07-22
2008-07-22
Li, Ruixiang (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S351000, C514S012200
Reexamination Certificate
active
07402657
ABSTRACT:
The present invention relates to isolated and/or recombinant C-C Chemokine Receptor 3 (CKR-3, CCR3) proteins or polypeptides.
REFERENCES:
patent: 5225538 (1993-07-01), Capon et al.
patent: 5284746 (1994-02-01), Sledziewski et al.
patent: 5470571 (1995-11-01), Herlyn et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5652133 (1997-07-01), Murphy
patent: 5707815 (1998-01-01), Charo et al.
patent: 6271347 (2001-08-01), Daugherty et al.
patent: 6537764 (2003-03-01), Gerard et al.
patent: 43 32 256 (1993-09-01), None
patent: 0 475 746 (1992-03-01), None
patent: 0 578 962 (1994-01-01), None
patent: WO 92/01810 (1992-02-01), None
patent: WO 94/05695 (1994-03-01), None
patent: WO 94/11504 (1994-05-01), None
patent: WO 95/31467 (1994-05-01), None
patent: WO 94/12635 (1994-06-01), None
patent: WO 94/20142 (1994-09-01), None
patent: WO 94/28931 (1994-12-01), None
patent: WO 95/08576 (1995-03-01), None
patent: WO 97/21812 (1997-06-01), None
patent: WO 97/22698 (1997-06-01), None
patent: WO 96/22371 (1997-07-01), None
patent: WO 97/41154 (1997-11-01), None
Springer, Timothy A., “Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm”,Cell, 76:301-314 (1994).
Murphy, Philip M., “The Molecular Biology of Leukocyte Chemoattractant Receptors”,Annu. Rev. Immunol., 12:593-633 (1994).
Baggiolini M., and Dahinden Clemens A., “CC Chemokines in Allergic Inflammation”,Immunology Today, 15(3):127-133 (1994).
Gerard N.P., and Gerard, C., “The Chemotactic Receptor for Human C5a Anaphylatoxin”,Nature, 349:614-617 (1991).
Neote, K., et al., “Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor”,Cell, 72:415-425 (1993).
Gao, J-L., et al., “Structure and Functional Expression of the Human Macrophage Inflammatory Protein 1α/RANTES Receptor”,J. of Exp. Med., 177:1421-1427 (1993).
Charo, I.F., et al., “Molecular Cloning and Functional Expression of Two Monocyte Chemoattractant Protein 1 Receptors Reveals Alternative Splicing of the Carboxyl-terminal Tails”,Proc. Natl. Acad. Sci. USA, 91:2752-2756 (1994).
Van Riper, G., et al., “Induction, Characterization, and Functional Coupling of the High Affinity Chemokine Receptor for RANTES and Macrophage Inflammatory Protein-1α upon Differentiation of an Eosinophilic HL-60 Cell Line”,J. of Immunol., 152:4055-4061 (1994).
Bischoff, S.C., et al., “RANTES and Related Chemokines Activate Human Basophil Granulocytes Through Different G Protein-coupled Receptors”,Eur. J. Immunol., 23:761-767 (1993).
Dahinden, C.A., et al., “Monocyte Chemotactic Protein 3 Is a Most Effective Basophil- and Eosinophil-activating Chemokine”,J. Exp. Med., 179:751-756 (1994).
Lefkowitz, R.J., “Turned On to Ill effect”,Nature, 365:603-604 (1993).
Clapham, D.E., “Mutations in G Protein-Linked Receptors” Novel Insights on Disease,Cell, 75:1237-1239 (1993).
Ponath, P.D., “C-C Chemokine Receptor 3: Identification of a Major Eosinophil Chemotactic Cytokine Receptor”, In: Conference Schedule for conference entitled “On the Cutting Edge of Anti-Inflammatory Drug Discovery” (Jan. 1995).
Combadiere, C., et al., “Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor”,J. of Biol. Chem., 270(27):16491-16494 (1995).
Combadiere, C., et al.,Correction, “Cloning and functional expression of a human Eosinophil CC Chemokine Receptor”,J. Biol. Chem., 270:30235 (1995).
Post, T.W., et al., “Molecular Characterization of Two Murine Eosinophil β Chemokine Receptors”,J. of Immunol., 155:5299-5305 (1995).
Gao, J-L., and Murphy, P.M., “Cloning and Differential Tissue-specific Expression of Three Mouse β Chemokine Receptor-like Genes, Including the Gene for a Functional Macrophage Inflammatory Protein-1α Receptor”,J. of Biol. Chem., 270(29):17494-17501 (1995).
Ponath, P.D., et al., “Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils”,J. Exp. Med., 183:2437-2448 (1996).
Daugherty B.L., et al., “Cloning, Expression, and Characterization of the Human Eosinophil Eotaxin Receptor”,J. Exp. Med., 183:2349-2354 (1996).
Kitaura, M., et al., “Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3”,J. of Biol. Chem., 271(13):7725-7730 (1996).
Jose, P.J., et al., “Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation”,J. Exp. Med., 179:881-887 (1994).
Förster, R., et al., “A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA”,Biochem. and Biophys. Res. Comm., 196(3):1496-1503 (1993).
Ponath, P.D., et al., “Cloning of the Human Eosinophil Chemoattractant, Eotaxin Expression, Receptor Binding, and Functional Properties Suggest a Mechanism for the Selective Recruitment of Eosinophils”,Jour. of Clinical Invest., 97(3):604-612 (1996).
Chaudhuri, A., et al., “Expression of the Duffy antigen in K562 Cells”,J. Biol. Chem., 269(11):7835-7838 (1994).
Szigeti, V., and Miller R.H., “A Cell Surface Antigen Expressed by Astrocytes and Their Precursors,”GLIA, 8:20-32 (1993).
Gillaspy, G.E., et al., “Antigenic and Differentiative Heterogeneity Among Human Glioblastomas,”Cancer Letters, 68:215-224 (1993).
Lyon, J.A., et al., “Monoclonal Antibody Characterization of the 195-Kilodalton Major Surface Glycoprotein ofPlasmodium falciparumMalaria Schizonts and Merozoites: Identification of Additional Processed Products and a Serotype-Restricted Repetitive Epitope,”J. Immunol., 138(3):895-901 (1987).
Forssmann, U., et al., “Eotaxin-2, a Novel CC Chemokine that is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes,”J. Exp. Med., 185(12):2171-2176 (1997).
Heath, H., et al., “Chemokine Receptor Usage by Human Eosinophils,”J. Clin. Invest., 99(2):178-184 (1997).
Sabroe, I., et al., “Cloning and Characterization of the Guinea Pig Eosinophil Eotaxin Receptor, C-C Chemokine Receptor-3: Blockade Using a Monoclonal Antibody In Vivo,”The Journal of Immunology, 161:6139-6147 (1998).
Chuntharapai, A. and K. Jin Kim, “Generation of Monoclonal Antibodies to Chemokine Receptors,”Methods in Enzymology, 288:15-27 (1997).
Murphy, P.M. et al., “International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors,”Pharmacol. Rev., 52(1):145-176 (2000).
Harlow, et al., “Antibodies a Laboratory Manual,” Ch. 5., pp. 76, Cold Spring Harbor Laboratories (1988).
Lerner et al., “Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity,”Nature 299:592-596 (1982).
Yamagami et al., “cDNA Cloning and Functional Expression of a Human Monocyte Chemoattractant Protein 1 Receptor”,Biochem.&Biophys. Res. Comm. 202(2):1156-1162 (1994).
Debets, R. and Savelkoul, H.F.J., “Cytokine Antagonists and their Potential Therapeutic Use,”Immunol. Today 15(10):455-458 (1994).
Henderson, B. and Blake, S., “Therapeutic Potential of Cytokine Manipulation,”Trends Pharmacol. Sci. 13(4):145-152 (1992).
Ngo, J.T., et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox.” InThe Protein Folding Problem and Tertiary Structure Prediction, Merz, Jr., K.M., et als., eds. (Boston: Birkhäuser), pp. 433-506 (1994).
Navia, M.A. and Peattie, D.A., “Structure-based Drug Design: Applications in Immunopharmacology and Immunosuppression,”Immunol. Today 14:2
Gerard Craig J.
Gerard Norma P.
Mackay Charles R.
Ponath Paul D.
Post Theodore W.
Hamilton Brook Smith & Reynolds P.C.
Li Ruixiang
Millennium Pharmaceuticals Inc.
LandOfFree
C-C chemokine receptor 3 proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-C chemokine receptor 3 proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-C chemokine receptor 3 proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2797816